Metformin Hydrochloride Milpharm

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Milpharm, is a biguanide presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control elevated blood glucose levels.

GNH USA supplies Metformin Hydrochloride Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics, comprehensive documentation, and responsive technical support throughout the procurement process.

Metformin Hydrochloride is used within the antidiabetic drug class to improve glycaemic control in patients with type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose by decreasing hepatic glucose output and enhancing peripheral insulin sensitivity.

Metformin Hydrochloride may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Diarrhea: loose stools, usually early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Vitamin B12 deficiency: may develop with long‑term use. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: abnormal liver enzymes or hepatitis.

Metformin Hydrochloride requires careful patient assessment and monitoring to minimise risks.

- Renal function monitoring: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function assessment: evaluate liver enzymes in patients with known liver disease. - Heart failure evaluation: avoid in patients with unstable or acute congestive heart failure. - Concomitant medication review: consider drugs that may impair renal function or increase lactic acidosis risk. - Elderly patients: start at lower doses and monitor tolerance closely. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations, enhancing toxicity. - Alcohol: excessive intake heightens the chance of lactic acidosis.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment. - Beta‑blockers: can mask hypoglycaemic symptoms. - Other antidiabetic agents: combined therapy may increase risk of hypoglycaemia. - Warfarin: metformin may modestly affect INR, necessitating monitoring.